ZipCode Bio

ZipCode Bio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Founded in 2019, ZipCode Bio is a private, early-stage biotech focused on the intersection of genetics, diagnostics, and advanced technologies like A.I. and delivery systems. The company's strategy is centered on building partnerships to co-develop its platform, which targets personalized medicine applications. Based on its website and limited public data, it is likely in a pre-revenue, platform-building stage, with its specific pipeline programs and leadership team not publicly disclosed. The company's success will hinge on validating its technological approach and securing strategic collaborations.

Genetics & GenomicsDiagnostics

Technology Platform

Integrated platform combining Artificial Intelligence (A.I.) for genetic data analysis with novel extra-hepatic delivery technologies for targeted genetic medicine applications.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The company operates at the high-growth intersection of AI-driven diagnostics and next-generation genetic medicine delivery.
Successfully proving its platform could make it an attractive partner for large pharma companies struggling with the extra-hepatic delivery challenge, enabling lucrative collaboration deals.

Risk Factors

The company faces extreme technical risk in developing a reliable extra-hepatic delivery system, a problem that has eluded many.
Its partnership-dependent business model creates execution risk, and as a pre-revenue private company, it is vulnerable to shifts in the venture capital funding environment.

Competitive Landscape

ZipCode Bio competes in two crowded and cutting-edge fields: AI/ML for genomics (e.g., Tempus, Sophia Genetics) and novel delivery platforms for genetic medicines (e.g., Dyno Therapeutics, Ring Therapeutics, many large biopharma internal efforts). Its differentiation hinges on uniquely combining these capabilities and demonstrating superior efficacy.